Patients | All | lcSSc | dcSSc |
---|---|---|---|
Gender, males/females, n | 19/102 | 3/76 | 16/26 |
Age, mean ± SD (range) years | 57 ± 12 (22-79) | 59 ± 11 | 55 ± 12 |
Disease duration, mean ± SD (range) years | 12 ± 9 (0-53) | 12 ± 9 | 11 ± 9 |
Cutaneous Involvement | |||
ᅟModified Rodnan skin score, mean ± SD | 11 ± 9 | 7 ± 3 | 20 ± 9 |
ᅟCutaneous ulcers, all, n | 68 | 44 | 24 |
ᅟCutaneous ulcers, present, n | 23 | 10 | 13 |
ᅟCutaneous ulcers, past, n | 45 | 34 | 11 |
ᅟCalcinosis, n (N)* | 43 (107) | 30 | 13 |
Pulmonary and Cardiac involvement | |||
ᅟDLCO, mean ± SD % predicted (N)* | 64.6 ± 19.9 (118) | 64.2 ± 18.5 (77) | 66.3 ± 20.3 (41) |
ᅟPatients with DLCO < 80 (%) | 75 % | 79 % | 74 % |
ᅟFVC, mean ± SD % predicted (N)* | 95.7 ± 21.1 (118) | 99.3 ± 20.1 (77) | 89.1 ± 21.7 (41)** |
ᅟPatients with FVC < 80 (%) | 22 % | 20 % | 27 % |
ᅟRadiographically confirmed lung fibrosis, n | 21 | 14 | 7 |
ᅟElevated SPAP by echocardiography, n (N)* | 10 (115) | 6 | 4 |
Serology | |||
ᅟAnti-nuclear antibodies, n | 116 | 74 | 42 |
ᅟAnti-Scl-70 antibodies, n | 15 | 3 | 12 |
ᅟAnti-centromere antibodies, n | 49 | 41 | 8 |
ᅟPeripheral blood | |||
ᅟLeukocytes total, mean ± SD (x 109/L) | 7.2 ± 2.2 | 7.4 ± 2.5 | 7.1 ± 2.3 |
ᅟNeutrophils, mean ± SD, (x 109/L) | 4.6 ± 1.8 | 4.7 ± 2.0 | 4.4 ± 1.6 |
ᅟPlatelets, mean ± SD, (x 109/L) | 275 ± 86 | 265 ± 86 | 268 ± 72 |
Others | |||
ᅟDMARDS, n | 8 | 4 | 4 |
ᅟCurrent or previous smokers, n | 83 | 57 | 26 |
ᅟArterial hypertension, n | 30 | 18 | 12 |